Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
PTB
MCID: PLM001
MIFTS: 69

Pulmonary Tuberculosis (PTB)

Categories: Infectious diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pulmonary Tuberculosis

About this section

MalaCards integrated aliases for Pulmonary Tuberculosis:

Name: Pulmonary Tuberculosis 12 15 17
Tuberculosis, Pulmonary 74 43 71
Tuberculosis Pulmonary 54
Ptb 47

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Respiratory diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:2957
ICD9CM 34 011
MeSH 43 D014397
NCIt 49 C26899
SNOMED-CT 67 154283005
ICD10 32 A15
UMLS 71 C0041327
Sources

Summaries for Pulmonary Tuberculosis

About this section
Disease Ontology : 12 A tuberculosis that is a contagious disease located in lungs. The infection has symptom fever, has symptom cough, has symptom difficulty in breathing, has symptom inflammatory infiltrations, has symptom formation of tubercles, has symptom caseation, has symptom pleural effusion, and has symptom fibrosis.

MalaCards based summary : Pulmonary Tuberculosis, also known as tuberculosis, pulmonary, is related to miliary tuberculosis and silicosis, and has symptoms including fever, cough and pleural effusion. An important gene associated with Pulmonary Tuberculosis is MBL2 (Mannose Binding Lectin 2), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Calcium carbonate and Tranexamic Acid have been mentioned in the context of this disorder. Affiliated tissues include lungs, lung and testes, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 74 Tuberculosis (TB) is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria.... more...

Sources

Related Diseases for Pulmonary Tuberculosis

About this section

Diseases related to Pulmonary Tuberculosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1028)
# Related Disease Score Top Affiliating Genes
1 miliary tuberculosis 32.9 IL12RB1 IFNGR1 IFNG ADA
2 silicosis 31.4 IL4 IL18 IL10
3 purpura 31.3 IL4 IL10 IFNG
4 pleurisy 31.2 TLR2 IL2 IFNG CCL3 ADA
5 viral hepatitis 31.1 TLR2 IL4 IL2 IL10 IFNG
6 appendicitis 31.1 IL2 IL10 IFNG
7 echinococcosis 31.1 TLR2 IL10 IFNG
8 allergic bronchopulmonary aspergillosis 31.1 MBL2 IL4 IL10 IFNG
9 bacterial pneumonia 31.1 TLR2 IL10 CCL3 ADA
10 tuberculous meningitis 31.0 TLR2 NAT2 CCL3 ADA
11 allergic hypersensitivity disease 31.0 IL4 IL2 IL10 IFNG CCL3
12 leprosy 3 31.0 VDR TLR2 SLC11A1 IL4 IL2 IL10
13 abdominal tuberculosis 31.0 IL12RB1 IFNG ADA
14 cryptococcosis 31.0 MBL2 IL4 IL10 IFNG
15 aspergillosis 31.0 TLR2 MBL2 IL4 IL18 IL10 IFNG
16 lung disease 31.0 TLR2 SLC11A1 MBL2 IL4 IL18 IL10
17 mycobacterium fortuitum 30.9 IL12RB1 IFNGR1
18 hepatitis a 30.9 IL4 IL10 IFNG
19 pneumonia 30.9 TLR2 MBL2 IL4 IL2 IL18 IL10
20 exanthem 30.9 IL2 IL10 IFNG
21 erythema multiforme 30.9 IL4 IL2 IFNG
22 multidrug-resistant tuberculosis 30.9 VDR SLC11A1 INHA IL10 IFNG
23 nontuberculous mycobacterial lung disease 30.9 TLR2 SLC11A1 IL12B
24 extrapulmonary tuberculosis 30.8 VDR TLR2 SLC11A1 MBL2 IL10 IFNGR1
25 candidiasis 30.8 TLR2 MBL2 IL4 IL2 IL10 IFNG
26 tuberculous peritonitis 30.8 IFNG ADA
27 interstitial lung disease 30.8 IL4 IL18 IL10 IFNG
28 neutropenia 30.8 MBL2 IL2 IL10 IFNG
29 herpes zoster 30.8 TLR2 IL2 IL10 IFNG
30 nocardiosis 30.7 IL12RB1 IFNG
31 pyelonephritis 30.7 MBL2 IL10 IFNG
32 human immunodeficiency virus type 1 30.7 IL2 IL12B IL10 IFNG CCL3 ADA
33 filariasis 30.7 TLR2 IL2 IL10 IFNG
34 ige responsiveness, atopic 30.7 IL4 IL10 IFNG
35 hypereosinophilic syndrome 30.7 IL4 IL2RA IL2 IL10 IFNG
36 bronchiolitis obliterans 30.6 TLR2 IL10 IFNG
37 endocarditis 30.6 TLR2 IL10 IFNG
38 peritonitis 30.6 TLR2 IL4 IL18 IL10 IFNG ADA
39 bronchiolitis 30.6 TLR2 IL4 IL10 IFNG CCL3
40 typhoid fever 30.5 SLC11A1 IFNGR1 IFNG
41 pulmonary disease, chronic obstructive 30.5 TLR2 MIR144 IL4 IL10 CCL3
42 acquired immunodeficiency syndrome 30.5 IL2RA IL2 IL10 IFNG CCL3 ADA
43 pleural tuberculosis 30.5 IL2RA IL18 IFNG CCL3 ADA
44 alopecia 30.5 VDR IL4 IL2 IFNG
45 coccidioidomycosis 30.5 MBL2 IL12RB1 IFNGR1
46 ileus 30.5 IL10 IFNG CCL3
47 measles 30.5 TLR2 IL2RA IL2 IFNG
48 meningitis 30.5 TLR2 MBL2 IL4 IL2 IL18 IL10
49 tonsillitis 30.4 TLR2 IL4 IL2 IL10 IFNG
50 cysticercosis 30.4 IL18 IL12B IL10

Comorbidity relations with Pulmonary Tuberculosis via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchiectasis
Bronchitis Deficiency Anemia
Heart Disease Iron Deficiency Anemia
Pleural Tuberculosis Postinflammatory Pulmonary Fibrosis
Protein-Energy Malnutrition Respiratory Failure

Graphical network of the top 20 diseases related to Pulmonary Tuberculosis:



Diseases related to Pulmonary Tuberculosis
Sources

Symptoms & Phenotypes for Pulmonary Tuberculosis

About this section

Symptoms:

12
  • • fever
  • • cough
  • • pleural effusion
  • • difficulty in breathing
  • • inflammatory infiltrations
  • • formation of tubercles
  • • caseation
  • • fibrosis

UMLS symptoms related to Pulmonary Tuberculosis:


hemoptysis

MGI Mouse Phenotypes related to Pulmonary Tuberculosis:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.36 ADA HP IFNG IFNGR1 IL10 IL12B
2 homeostasis/metabolism MP:0005376 10.34 ADA HP IFNG IFNGR1 IL10 IL12B
3 digestive/alimentary MP:0005381 10.32 ADA IFNG IFNGR1 IL10 IL12B IL18
4 immune system MP:0005387 10.31 ADA HP IFNG IFNGR1 IL10 IL12B
5 cardiovascular system MP:0005385 10.26 ADA HP IFNG IFNGR1 IL10 IL18
6 growth/size/body region MP:0005378 10.26 ADA IFNG IL10 IL12B IL12RB1 IL18
7 endocrine/exocrine gland MP:0005379 10.19 ADA IFNG IFNGR1 IL10 IL2 IL2RA
8 mortality/aging MP:0010768 10.17 ADA HP IFNG IFNGR1 IL10 IL12B
9 liver/biliary system MP:0005370 10.02 ADA HP IFNG IFNGR1 IL10 IL2
10 neoplasm MP:0002006 9.91 HP IFNG IFNGR1 IL10 IL12B IL2
11 renal/urinary system MP:0005367 9.76 ADA HP IFNG IFNGR1 IL4 MBL2
12 respiratory system MP:0005388 9.56 ADA IFNG IL10 IL12B IL2 IL2RA
13 skeleton MP:0005390 9.36 ADA IFNG IFNGR1 IL10 IL12B IL2RA
Sources

Drugs & Therapeutics for Pulmonary Tuberculosis

About this section

Drugs for Pulmonary Tuberculosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 212)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Calcium carbonate Approved, Investigational Phase 4 471-34-1
2
Tranexamic Acid Approved Phase 4 1197-18-8 5526
3
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
4
Ethambutol Approved Phase 4 74-55-5 3279 14052
5
Pyrazinamide Approved, Investigational Phase 4 98-96-4 1046
6
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
7 Anti-Infective Agents Phase 4
8 Antiprotozoal Agents Phase 4
9 Antiparasitic Agents Phase 4
10 interferons Phase 4
11 Antiviral Agents Phase 4
12 Interferon-gamma Phase 4
13 Hemostatics Phase 4
14 Antifibrinolytic Agents Phase 4
15 Coagulants Phase 4
16 Immunologic Factors Phase 4
17 Immunosuppressive Agents Phase 4
18 Benzonidazole Phase 4
19 Antacids Phase 4
20 Proton Pump Inhibitors Phase 4
21 Anti-Ulcer Agents Phase 4
22 Gastrointestinal Agents Phase 4
23 Antitubercular Agents Phase 4
24 Lipid Regulating Agents Phase 4
25 Hypolipidemic Agents Phase 4
26 Antimetabolites Phase 4
27 Antibiotics, Antitubercular Phase 4
28
Rifampicin Approved Phase 3 13292-46-1 5381226 5458213
29
Zinc sulfate Approved, Investigational Phase 3 7733-02-0
30
Didanosine Approved Phase 3 69655-05-6 50599
31
Nitric Oxide Approved Phase 3 10102-43-9 145068
32
Cycloserine Approved Phase 2, Phase 3 68-41-7 401 6234
33
Aminosalicylic Acid Approved Phase 2, Phase 3 65-49-6 4649
34
Zinc Approved, Investigational Phase 3 7440-66-6 32051
35
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
36
leucovorin Approved Phase 3 58-05-9 6006 143
37
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
38
Hydroxocobalamin Approved Phase 3 13422-51-0 15589840 11953898
39
Copper Approved, Investigational Phase 3 7440-50-8 27099
40
Nicotine Approved Phase 3 54-11-5 942 89594
41
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
42
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
43
Prothionamide Approved, Investigational Phase 2, Phase 3 14222-60-7 666418
44
Kanamycin Approved, Investigational, Vet_approved Phase 2, Phase 3 59-01-8, 8063-07-8 6032
45
Azithromycin Approved Phase 3 83905-01-5 447043 55185
46
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
47
Permethrin Approved, Investigational Phase 3 52645-53-1 40326
48
Rifapentine Approved, Investigational Phase 3 61379-65-5 6323497
49
Bedaquiline Approved Phase 2, Phase 3 843663-66-1
50
Moxifloxacin Approved, Investigational Phase 2, Phase 3 354812-41-2, 151096-09-2 152946

Interventional clinical trials:

(show top 50) (show all 285)
# Name Status NCT ID Phase Drugs
1 The Impact of the Simple Verbal Intervention for Adequately Collecting Sputum and the Acceptable Specimen Based on Gram Stain, on the Results of Sputum Acid-fast Bacilli Smear Testing Unknown status NCT01135043 Phase 4
2 International Multicenter Trial for the Evaluation of a Four-Drug Fixed Dose Combined Tablet Daily in the Initial Intensive Phase of Chemotherapy Followed by a Two-Drug Fixed Dose Combined Tablet Three Times a Week in the Continuation Phase for the Treatment of Pulmonary Tuberculosis Unknown status NCT00216333 Phase 4 combined fixed dose combination
3 New Super-short Course Regimen for Retreatment Pulmonary Tuberculosis Unknown status NCT02331823 Phase 4 Isoniazid Aminosalicylate Tablets;Streptomycin injectable
4 Shortened Regimens for First Diagnosed Smear Positive Drug Susceptible Pulmonary Tuberculosis: a Randomised Controlled Non-inferiority Trial Unknown status NCT02901288 Phase 4 Isoniazid;Rifampicin;Pyrazinamide;Ethambutol;Levofloxacin
5 Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis in the National Institute of Respiratory Diseases Unknown status NCT02464683 Phase 4
6 Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis (EVIDENT Study): a Randomized, Double Blind, Controlled Trial Unknown status NCT02169570 Phase 4
7 Different Reintroduction Regimens of Antituberculosis Drugs After Development of Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
8 Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT) Completed NCT00298870 Phase 4 Isoniazid;isoniazed
9 Multicenter Open Non-Comparative Clinical Study to Evaluate the Efficacy and Safety of Three Months TAVANIC Course (Levofloxacin) in Combine Treatment of Multi-Drug-Resistant Tuberculosis (MDR-TB) Completed NCT00495339 Phase 4 Levofloxacin
10 Pilot Roll Out of the Xpert MTB/Rif for the Diagnosis of Pulmonary Tuberculosis in Two Municipalities in Brazil: a Stepped Wedge Trial Completed NCT01363765 Phase 4
11 Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation: a National Multicenter Randomized Clinical Trial Completed NCT02231229 Phase 4 conventional therapy
12 A Randomised Control Trial on the Effectiveness of Three Modalities of Tuberculosis Treatment Supervision Under DOTS Strategy in Ethiopia. Completed NCT00939419 Phase 4
13 Tranexamic Acid Contribution in the Prevention of Perioperative Bleeding in Pulmonary Resection Surgery Completed NCT04224116 Phase 4 Tranexamic acid injection;SSI
14 Cost-effectiveness of Quantiferon Gold in VITRO Test of T-lymphocytic Response for Detection of Latent Tuberculosis in At-risk Healthcare Workers Completed NCT00797836 Phase 4
15 Investigation of a Novel Approach to Improve Adherence to Treatment and Treatment Success Rates for Tuberculosis Patients in Senegal Completed NCT00412009 Phase 4
16 Optimization of Sampling Procedure for PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Treated With Benznidazole in Aiquile, Bolivia Completed NCT01678599 Phase 4 Benznidazole
17 Secondary Prevention With Long-term Oral Esomeprazole for Peptic Ulcer Recurrence and Rebleeding in High-risk Rockall Scores ≥ 6 Patients Recruiting NCT02456012 Phase 4 oral esomeprazole 20 mg twice daily;oral esomeprazole 20 mg once daily
18 Pilot Clinical Trial of PRS TB Regimen I - Phase II Enrolling by invitation NCT03561753 Phase 4 Group A (the standard 2HRZE/4HR regimen）;Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)
19 Primary Prophylaxis for Prevention of TB in Prison's Populations Terminated NCT03028129 Phase 4 Isoniazid 900 milligrams;Placebo
20 A Randomised Open-Label Controlled Trial of a 4-Month Gatifloxacin-Containing Regimen Versus Standard Regimen for the Treatment of Adult Patients With Pulmonary Tuberculosis Unknown status NCT00216385 Phase 3 Gatifloxacin combined regimen
21 A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects With Pulmonary Tuberculosis Unknown status NCT02467608 Phase 2, Phase 3 Isoniazid with HUEXC030 and RZE;HRZE
22 Efficacy of Oral Zinc Administration as an Adjunct Therapy in Category I Pulmonary Tuberculosis Along With Assessment of Immunological Parameters (Double-blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial Unknown status NCT00698386 Phase 3
23 Characterization of Immune Responses in Treatment-induced Latency in Pulmonary Tuberculosis Unknown status NCT01154959 Phase 3 Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol
24 Role of Oral Vitamin D as an Adjunct Therapy in Category I Pulmonary Tuberculosis Along With Assessment of Immunological Parameters. (Double-blind, Randomized, Placebo-Controlled, Clinical Trial) Unknown status NCT00507000 Phase 3 Cholecalciferol;Lactose granules
25 Evaluation of Safety and Efficacy of Two Different Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment in Patients With HIV-1 and Tuberculosis Unknown status NCT00332306 Phase 3 Didanosine, Lamivudine, Efavirenz;Didanosine, Lamivudine, Nevirapine
26 TBTC Study 31 PK/PD: Population Pharmacokinetic and Pharmacodynamic Study of Efficacy and Safety of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis in the Study 31 Treatment Trial: Intensive PK Sampling Unknown status NCT02563327 Phase 3 Rifapentine;Moxifloxacin;Rifampin;Isoniazid;Pyrazinamide;Ethambutol
27 Trial of Adjunctive Vitamin D in Tuberculosis Treatment Completed NCT00419068 Phase 3 Cholecalciferol;Migliol Placebo Oil
28 A Phase 3 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 4 and 6 Months of Treatment in Adult Subjects With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis and After 6 Months of Treatment in Adult Subjects With Multi-Drug Resistant, Smear-Positive Pulmonary Tuberculosis. Completed NCT02342886 Phase 3 Moxifloxacin;PA-824;Pyrazinamide;HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination);HR (rifampicin plus isoniazid combination tablets)
29 Phase 3 Trial of Oral L-arginine and / or Vitamin D as Adjunctive Therapies in Pulmonary Tuberculosis in Papua Province, Indonesia. Completed NCT00677339 Phase 3 L-arginine;Vitamin D;Placebo L-arginine;Placebo Vitamin D
30 A Double Blind, Randomized, Parallel, Placebo Control Design Study to Determine the Effect of Addition of Vitamin D to Conventional Anti TB Therapy Completed NCT00366470 Phase 3 A. 100,000 IU Cholecalciferol per dose of 3.3ml
31 Adjunct Vitamin A Therapy for Tuberculosis and HIV/AIDS Completed NCT00057434 Phase 3 multivitamin
32 TBTC Study 22: Efficacy and Safety of Once-Weekly Rifapentine and Isoniazid Compared to Efficacy and Safety of Once-Weekly Rifapentine and Isoniazid Compared to Twice-Weekly Rifampin and Isoniazid in the Continuation Phase of Therapy for Pulmonary Tuberculosis Completed NCT00023335 Phase 3 Rifapentine;Isoniazid
33 Micronutrient Supplementation in Conjunction With Standard Anti-Tuberculosis Therapy in Paediatric (6 Months-15 Years) New Pulmonary Tuberculosis Patients Completed NCT00801606 Phase 3 Zinc;Micronutrient without zinc;Micronutrient with zinc;Placebo
34 Efficacy and Safety of Immunomodulator (Mycobacterium w.) as an Adjunct Therapy in Category I Pulmonary Tuberculosis and Along With Assessment of Immunological Parameters Completed NCT00341328 Phase 3
35 Efficacy and Safety Study of Immunomodulator (Mycobacterium w) as an Adjunct Therapy in Category-II Pulmonary Tuberculosis Along With Assessment of Immunological Parameters Completed NCT00265226 Phase 3
36 The Treatment of Pulmonary Mycobacterium Tuberculosis in HIV Infection Completed NCT00001033 Phase 3 Ethambutol hydrochloride;Isoniazid;Pyrazinamide;Pyridoxine hydrochloride;Levofloxacin;Rifampin
37 Impact of a Package of Intensive Smoking-cessation Interventions Versus Smoking-cessation Advice on Outcomes in Smear-positive Patients With Pulmonary Tuberculosis; a Randomised Controlled Trial (STB_RCT). Completed NCT01517022 Phase 3 nicotine replacement therapy
38 A Randomised Placebo - Controlled Double Blind Trial Comparing 1) a Two Month Intensive Phase of Ethambutol, Moxifloxacin, Rifampicin, Pyrazinamide Versus the Standard Regimen (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide) and 2) a Treatment Shortening Regimen Comparing Two Months Moxifloxacin, Isoniazid, Rifampicin, Pyrazinamide Followed by Two Months Moxifloxacin, Isoniazid, Rifampicin Versus the Standard Regimen (Two Months Ethambutol, Isoniazid, Rifampicin, Pyrazinamide Followed by Four Months Isoniazid and Rifampicin) for the Treatment of Adults With Pulmonary Tuberculosis Completed NCT00864383 Phase 3 Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin
39 Optimization of the TB Treatment Regimen Cascade Completed NCT02153528 Phase 3 double rimfampicin;Standard TB treatment
40 A Randomized Controlled Clinical Trial Comparing Daily Vs. Intermittent 6 - Month Short Course Chemotherapy in Reducing Failures & Emergence of Acquired Rifampicin Resistance (ARR) in Patients With HIV and Pulmonary Tuberculosis Completed NCT00933790 Phase 3 ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)
41 The Role of Nutritional Support and Diabetes During Treatment of Pulmonary TB: Two Randomized Nutritional Supplementation Trials in Tanzania Completed NCT00311298 Phase 3
42 Trial of Vitamin D in HIV Progression Completed NCT01798680 Phase 3
43 A Randomized Control Trial Of High-Dose Isoniazid Adjuvant Therapy For Multidrug Resistant Tuberculosis Completed NCT00513396 Phase 2, Phase 3 Isoniazid;Placebo
44 A Multi-centric Study on Treatment of Abdominal Tuberculosis (Intestinal or Peritoneal): A Randomized Controlled Trial to Compare the 6 Months of Cat I Treatment With 9 Months of Cat I Treatment (Extension for 3 Months) in Abdominal Tuberculosis Under the Revised National Tuberculosis Control Program Completed NCT01124929 Phase 3 RNTCP Category I treatment for 6 months;RNTCP Category I treatment for 9months
45 DARDAR Health Project (Disseminated Tuberculosis and HIV Infection) Completed NCT00052195 Phase 2, Phase 3
46 A Prospective Study of Shortening the Duration of Standard Short Course Chemotherapy From 6 Months to 4 Months in HIV-non-infected Patients With Fully Drug-Susceptible, Non-cavitary Pulmonary Tuberculosis With Negative Sputum Cultures After 2 Months of Anti-TB Treatment Completed NCT00130247 Phase 3 Ethambutol;Isoniazid;Pyrazinamide;Rifampin
47 Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis Recruiting NCT03474198 Phase 2, Phase 3 Rifampicin;Isoniazid;Pyrazinamide;Ethambutol;Linezolid;Clofazimine;Rifapentine;Levofloxacin;Bedaquiline;Rifampicin
48 An International Multicentre Controlled Clinical Trial to Evaluate 1200mg and 1800mg Rifampicin Daily for Four Months in the Reduction of the Duration of Standard Treatment of Pulmonary Tuberculosis Recruiting NCT02581527 Phase 3 Rifampicin;Isoniazid;Ethambutol;Pyrazinamide
49 Evaluating Newly Approved Drugs for Multidrug-resistant TB (endTB): A Clinical Trial Recruiting NCT02754765 Phase 3 Bedaquiline;Delamanid;Clofazimine;Levofloxacin;Moxifloxacin;Linezolid;Pyrazinamide;Control arm MDR-TB regimen, consistent with WHO guidelines
50 A Randomised, Controlled, Open-Label, Phase II-III Trial to Evaluate the Safety and Efficacy of Regimens Containing Bedaquiline and Pretomanid for the Treatment of Adult Patients With Pulmonary Multidrug Resistant Tuberculosis Recruiting NCT02589782 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.

Search NIH Clinical Center for Pulmonary Tuberculosis

Cochrane evidence based reviews: tuberculosis, pulmonary

Sources

Genetic Tests for Pulmonary Tuberculosis

About this section
Sources

Anatomical Context for Pulmonary Tuberculosis

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Pulmonary Tuberculosis:

19
Lungs

MalaCards organs/tissues related to Pulmonary Tuberculosis:

40
Lung, Testes, Liver, T Cells, Heart, Skin, Lymph Node
Sources

Publications for Pulmonary Tuberculosis

About this section

Articles related to Pulmonary Tuberculosis:

(show top 50) (show all 30135)
# Title Authors PMID Year
1
Role of interferon-gamma release assays in the diagnosis of pulmonary tuberculosis in patients with advanced HIV infection. 61 54
20302657 2010
2
Association of reduced tumor necrosis factor alpha, gamma interferon, and interleukin-1beta (IL-1beta) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis. 61 54
20007364 2010
3
Interferon gamma gene +874A/T polymorphism and intracellular interferon gamma expression in pulmonary tuberculosis. 54 61
20004112 2010
4
P2X7 gene polymorphisms and risk assessment for pulmonary tuberculosis in Asian Indians. 54 61
20164546 2010
5
Association between FokI polymorphism in vitamin D receptor gene and susceptibility to spinal tuberculosis in Chinese Han population. 61 54
20430254 2010
6
[Development and use of a domestic test system for diagnosis of tuberculous infection on the basis of quantitative analysis of interferon-gamma induction in whole blood samples in vitro, by using specific recombinant antigens]. 61 54
20201379 2010
7
Variants in toll-like receptors 2 and 9 influence susceptibility to pulmonary tuberculosis in Caucasians, African-Americans, and West Africans. 54 61
19771452 2010
8
Vitamin D receptor homozygote mutant tt and bb are associated with susceptibility to pulmonary tuberculosis in the Iranian population. 61 54
19482503 2010
9
Infection with Mycobacterium tuberculosis Beijing genotype strains is associated with polymorphisms in SLC11A1/NRAMP1 in Indonesian patients with tuberculosis. 61 54
19863441 2009
10
Rapid diagnosis of active pulmonary tuberculosis in the elderly using enzyme-linked immunospot assay for interferon-gamma. 54 61
20121995 2009
11
BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay. 54 61
19715782 2009
12
Allelic polymorphism of cytokine genes during pulmonary tuberculosis. 61 54
20027321 2009
13
Diagnosis of pulmonary tuberculosis among dialysis patients by enzyme-linked immunospot assay for interferon-gamma. 61 54
19474277 2009
14
Engagement of Toll-like receptor 2 on CD4(+) T cells facilitates local immune responses in patients with tuberculous pleurisy. 61 54
19552525 2009
15
Plasma 1,25 dihydroxy vitamin D3 level and expression of vitamin d receptor and cathelicidin in pulmonary tuberculosis. 61 54
19219539 2009
16
Adenosine deaminase activity and its isoenzymes in the sputum of patients with pulmonary tuberculosis. 54 61
19460251 2009
17
[Case of pulmonary tuberculosis with miliary granules, mediastinal lymph node enlargement and elevation of soluble interleukin-2 receptor]. 54 61
19588853 2009
18
[A study on the haplotype of the solute carrier family 11 member 1 gene in Tibetan patients with pulmonary tuberculosis in China]. 61 54
19799071 2009
19
Analysis of discordance between the tuberculin skin test and the interferon-gamma release assay. 61 54
19335949 2009
20
Role played by human mannose-binding lectin polymorphisms in pulmonary tuberculosis. 61 54
19199550 2009
21
Regulatory role of 1, 25-dihydroxyvitamin D3 and vitamin D receptor gene variants on intracellular granzyme A expression in pulmonary tuberculosis. 61 54
19014932 2009
22
[A case of pulmonary tuberculosis and tuberculous pleuritis during treatment with etanercept for rheumatoid arthritis]. 54 61
19260544 2009
23
Effect of 1,25 dihydroxyvitamin D3 on intracellular IFN-gamma and TNF-alpha positive T cell subsets in pulmonary tuberculosis. 54 61
19091593 2009
24
The impact of HIV infection and CD4 cell count on the performance of an interferon gamma release assay in patients with pulmonary tuberculosis. 54 61
19156218 2009
25
Compartmentalized bronchoalveolar IFN-gamma and IL-12 response in human pulmonary tuberculosis. 61 54
18848499 2009
26
[In vitro interferon-gamma induction in whole blood samples is a test for tuberculous infection in children and adolescents]. 54 61
19642569 2009
27
Markedly-elevated serum CA125 in a woman with pulmonary tuberculosis. 54 61
19224069 2009
28
[Modulatory effect of isoniazid and rifampicin in vitro on cytokine secretion in pulmonary tuberculosis]. 54 61
19697859 2009
29
[Diagnostic value of interferon-gamma in the serum of patients with pulmonary tuberculosis and lung cancer diseases]. 54 61
19810179 2009
30
Impaired gamma interferon response to Mycobacterium vaccae antigens in patients with cavitary pulmonary tuberculosis. 61 54
18596204 2008
31
Differential expression of interleukin-4 (IL-4) and IL-4 delta 2 mRNA, but not transforming growth factor beta (TGF-beta), TGF-beta RII, Foxp3, gamma interferon, T-bet, or GATA-3 mRNA, in patients with fast and slow responses to antituberculosis treatment. 61 54
18579694 2008
32
Cytokine gene polymorphisms and cytokine levels in pulmonary tuberculosis. 61 54
18522869 2008
33
Interleukin-12 receptor beta1 polymorphisms and nontuberculous mycobacterial lung diseases. 61 54
18493823 2008
34
Regulatory role of promoter and 3' UTR variants of vitamin D receptor gene on cytokine response in pulmonary tuberculosis. 54 61
18231846 2008
35
Comparison of sensitivities of two commercial gamma interferon release assays for pulmonary tuberculosis. 61 54
18400912 2008
36
Enhancement of diagnostic efficiency by a gamma interferon release assay for pulmonary tuberculosis. 61 54
18400971 2008
37
A new protocol for multiple inhalation of IFN-gamma successfully treats MDR-TB: a case study. 61 54
18492330 2008
38
Regulatory region polymorphisms of vitamin D receptor gene in pulmonary tuberculosis patients and normal healthy subjects of south India. 61 54
18397302 2008
39
Accuracy of an interferon-gamma release assay to detect active pulmonary and extra-pulmonary tuberculosis. 61 54
18284831 2008
40
Immune response to Nocardia brasiliensis extracellular antigens in patients with mycetoma. 61 54
18302006 2008
41
Diagnostic accuracy of cytokine levels (TNF-alpha, IL-2 and IFN-gamma) in bronchoalveolar lavage fluid of smear-negative pulmonary tuberculosis patients. 61 54
17975298 2008
42
[Plasma levels of cytokines in patients with active infiltrative pulmonary tuberculosis]. 54 61
18819336 2008
43
SLC11A1 (formerly NRAMP1) polymorphisms associated with multidrug-resistant tuberculosis. 61 54
17950034 2008
44
[Modulation of an antituberculous immune response in vitro, by using antigen-activated dendritic cells]. 61 54
18368774 2008
45
Validity of the CA125 level in the differential diagnosis of pulmonary tuberculosis. 54 61
18219138 2008
46
CD14 C(-159)T polymorphism is a risk factor for development of pulmonary tuberculosis. 61 54
18008256 2007
47
Genetic polymorphisms in alveolar macrophage response-related genes, and risk of silicosis and pulmonary tuberculosis in Chinese iron miners. 54 61
17223386 2007
48
Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. 61 54
17950035 2007
49
Rifampin levels, interferon-gamma release and outcome in complicated pulmonary tuberculosis. 61 54
17890156 2007
50
Polymorphisms of interferon-gamma and interferon-gamma receptor 1 genes and pulmonary tuberculosis in Koreans. 54 61
17986123 2007
Sources

Variations for Pulmonary Tuberculosis

About this section
Sources

Expression for Pulmonary Tuberculosis

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Pulmonary Tuberculosis patients vs. healthy controls: 35 (show all 44)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 GBP6 guanylate binding protein family, member 6 Blood + 4.38 0.000
2 ANKRD22 ankyrin repeat domain 22 Blood + 4.04 0.000
3 PDCD1LG2 programmed cell death 1 ligand 2 Blood + 4.03 0.000
4 RLTPR RGD motif, leucine rich repeats, tropomodulin domain and proline-rich containing Blood - 3.89 0.000
5 CD274 CD274 molecule Blood + 3.87 0.000
6 CD248 CD248 molecule, endosialin Blood - 3.84 0.000
7 SPIB Spi-B transcription factor (Spi-1/PU.1 related) Blood - 3.81 0.000
8 LRRN3 leucine rich repeat neuronal 3 Blood - 3.61 0.000
9 LINC00668 long intergenic non-protein coding RNA 668 Blood + 3.60 0.000
10 C1QC complement component 1, q subcomponent, C chain Blood + 3.56 0.000
11 CR1 complement component (3b/4b) receptor 1 (Knops blood group) Blood + 3.54 0.000
12 AEBP1 AE binding protein 1 Blood - 3.53 0.000
13 KREMEN1 kringle containing transmembrane protein 1 Blood + 3.49 0.000
14 CACNA1E calcium channel, voltage-dependent, R type, alpha 1E subunit Blood + 3.46 0.000
15 LGALSL lectin, galactoside-binding-like Blood - 3.43 0.000
16 BATF2 basic leucine zipper transcription factor, ATF-like 2 Blood + 3.42 0.000
17 PLEKHB1 pleckstrin homology domain containing, family B (evectins) member 1 Blood - 3.40 0.000
18 CD22 CD22 molecule Blood - 3.38 0.000
19 BACH1 BTB and CNC homology 1, basic leucine zipper transcription factor 1 Blood + 3.38 0.000
20 NAIP NLR family, apoptosis inhibitory protein Blood + 3.34 0.000
21 EPHB6 EPH receptor B6 Blood - 3.30 0.000
22 DICER1 dicer 1, ribonuclease type III Blood + 3.26 0.000
23 MVD mevalonate (diphospho) decarboxylase Blood - 3.26 0.000
24 FBLN2 fibulin 2 Blood - 3.26 0.000
25 FBXL16 F-box and leucine-rich repeat protein 16 Blood - 3.23 0.000
26 CR2 complement component (3d/Epstein Barr virus) receptor 2 Blood - 3.21 0.000
27 PRSS33 protease, serine, 33 Blood - 3.21 0.000
28 FGF13 fibroblast growth factor 13 Blood + 3.20 0.000
29 GNPNAT1 glucosamine-phosphate N-acetyltransferase 1 Blood - 3.19 0.000
30 RTKN2 rhotekin 2 Blood - 3.19 0.000
31 EPHA1 EPH receptor A1 Blood - 3.16 0.000
32 APOL6 apolipoprotein L, 6 Blood + 3.16 0.000
33 CRIP2 cysteine-rich protein 2 Blood - 3.15 0.000
34 C1QB complement component 1, q subcomponent, B chain Blood + 3.15 0.000
35 CARD17 caspase recruitment domain family, member 17 Blood + 3.14 0.000
36 SERINC5 serine incorporator 5 Blood - 3.12 0.000
37 HKDC1 hexokinase domain containing 1 Blood - 3.11 0.000
38 NT5E 5'-nucleotidase, ecto (CD73) Blood - 3.10 0.000
39 LINC00342 long intergenic non-protein coding RNA 342 Blood + 3.10 0.000
40 PMEPA1 prostate transmembrane protein, androgen induced 1 Blood - 3.09 0.000
41 FCGBP Fc fragment of IgG binding protein Blood - 3.07 0.000
42 SALL2 spalt-like transcription factor 2 Blood - 3.06 0.000
43 GPA33 glycoprotein A33 (transmembrane) Blood - 3.02 0.000
44 SLC27A5 solute carrier family 27 (fatty acid transporter), member 5 Blood - 3.00 0.000
Search GEO for disease gene expression data for Pulmonary Tuberculosis.
Sources

Pathways for Pulmonary Tuberculosis

About this section

Pathways related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.98 TLR2 SLC11A1 PGM1 MBL2 IL4 IL2RA
2
PEDF Induced Signaling 63
Show member pathways
 13.72 INHA IL4 IL2RA IL2 IL18 IL12RB1
3
TGF-Beta Pathway 63
Show member pathways
 13.6 IL4 IL2RA IL2 IL18 IL12RB1 IL12B
4
Akt Signaling 63
Show member pathways
 13.47 TLR2 IL4 IL2RA IL2 IL18 IL12RB1
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.39 IL4 IL2RA IL2 IL18 IL12RB1 IL12B
6
PAK Pathway 63
Show member pathways
 13.35 IL4 IL2RA IL2 IL18 IL12RB1 IL12B
7
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.11 TLR2 MBL2 IL2 IL12B IL10 IFNGR1
8
Allograft rejection 1 36
Show member pathways
 12.91 IL4 IL2RA IL2 IL12B IL10 IFNG
9
Pathways in cancer 36
12.91 IL4 IL2RA IL2 IL12RB1 IL12B IFNGR1
10
Measles 36
Show member pathways
 12.88 TLR2 IL2RA IL2 IL18 IL12B IFNGR1
11
T cell receptor signaling pathway 36
Show member pathways
 12.67 TLR2 IL4 IL2 IL10 IFNGR1 IFNG
12
Immune response IL-23 signaling pathway 22
Show member pathways
 12.66 IL2 IL18 IL12RB1 IL12B IL10 IFNG
13
NF-kappaB Signaling 4
12.64 TLR2 IL4 IL2RA IL2 IL10 IFNG
14
Immune response NFAT in immune response 22
Show member pathways
 12.53 IL4 IL2RA IL2 IL18 IL12RB1 IL12B
15
Th17 cell differentiation 36
Show member pathways
 12.49 TLR2 IL4 IL2RA IL2 IL18 IL12RB1
16
JAK-STAT signaling pathway 36
Show member pathways
 12.46 IL4 IL2RA IL2 IL12RB1 IL12B IL10
17
Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.4 IL2RA IL2 IL18 IL10 CCL3
18
Toxoplasmosis 36
Show member pathways
 12.3 TLR2 IL4 IL12B IL10 IFNGR1 IFNG
19
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.28 IL4 IL2RA IL2 IL18 IL12B IL10
20
Bacterial infections in CF airways 22
Show member pathways
 12.21 TLR2 IL4 IFNGR1 IFNG
21
Tuberculosis 36
12.2 VDR TLR2 IL18 IL12B IL10 IFNGR1
22
Jak Stat Signaling Pathway 66
Show member pathways
 12.11 IL4 IL2RA IL2
23
Hematopoietic Stem Cells and Lineage-specific Markers 64
12.07 IL4 IL2RA IL2 IL10 IFNG
24
Interleukin-4 and 13 signaling 65
12.04 IL4 IL18 IL12B IL10
25
Amoebiasis 36
11.99 TLR2 IL12B IL10 IFNG
26
Rheumatoid arthritis 36
11.94 TLR2 IL18 IFNG CCL3
27
Th17 Differentiation 64
Show member pathways
 11.93 TLR2 IL4 IL12RB1 IL12B IFNG
28
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.84 IL4 IL2RA IL2 IFNG
29
IL12-mediated signaling events 1
Show member pathways
 11.81 IL4 IL2RA IL2 IL18 IL12RB1 IL12B
30
Glucocorticoid receptor regulatory network 1
11.8 IL4 IL2 IFNG
31
Dendritic Cells Developmental Lineage Pathway 64
11.75 IL2 IL10 IFNG
32
IL2 signaling events mediated by PI3K 1
Show member pathways
 11.71 IL4 IL2RA IL2
33
Lung fibrosis 1
11.68 IL4 IL12B CCL3
34
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.66 IL2RA IL2 IFNG
35
Legionellosis 36
11.63 TLR2 IL18 IL12B
36
Malaria 36
11.63 TLR2 IL18 IL10 IFNG
37
MSP-RON Signaling 63
11.6 TLR2 IL18 IL12B IFNG
38
Interleukin-10 signaling 65
11.58 IL4 IL18 IL12B IL10 CCL3
39
IL27-mediated signaling events 1
Show member pathways
 11.58 TLR2 IL2 IL18 IL12RB1 IL12B IL10
40
Aryl Hydrocarbon Receptor Pathway 1
11.55 IL2 IL12B IFNG
41
Th2 Differentiation 64
11.54 IL4 IL2RA IL2 IL10 IFNG
42
African trypanosomiasis 36
11.47 IL18 IL12B IL10 IFNG
43
Inflammatory Response Pathway 1
11.42 IL4 IL2RA IL2 IFNG
44
Development and heterogeneity of the ILC family 1
11.4 IL4 IL18 IL12B IFNG
45
IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types 64
Show member pathways
 11.39 IL2RA IL2 IL10 IFNG CCL3
46
Immune response_IL-12 signaling pathway 22
Show member pathways
 11.33 IL2RA IL12RB1 IL12B IFNG
47
IL12 signaling mediated by STAT4 1
11.31 IL2RA IL2 IL18 IFNG
48
IL1 and megakaryocytes in obesity 1
11.25 TLR2 IL18 IFNG
49
OX40 Pathway 63
11.25 IL4 IL2 IL10 IFNG
50
Cytokines and Inflammatory Response 1
11.23 IL4 IL2 IL12B IL10 IFNG
Sources

GO Terms for Pulmonary Tuberculosis

About this section

Cellular components related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 PGM1 MBL2 INHA IL4 IL2 IL18
2 extracellular space GO:0005615 9.4 MIR144 MBL2 INHA IL4 IL2 IL18

Biological processes related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.33 VDR TLR2 INHA IL4 IL18 IL12RB1
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.24 VDR TLR2 SLC11A1 IL4 IL2 IL18
3 inflammatory response GO:0006954 10.09 TLR2 SLC11A1 IL2RA IL18 CCL3
4 MAPK cascade GO:0000165 10.03 IL2RA IL2 IL18 CCL3
5 defense response to bacterium GO:0042742 10.02 SLC11A1 MBL2 IL10 HP
6 cell-cell signaling GO:0007267 10.02 INHA IL2 IL18 CCL3
7 immune response GO:0006955 9.97 TLR2 SLC11A1 IL4 IL2RA IL2 IL18
8 negative regulation of inflammatory response GO:0050728 9.92 IL4 IL2RA IL2 IL10 ADA
9 response to organic substance GO:0010033 9.91 IL12B IL10 HP
10 positive regulation of gene expression GO:0010628 9.91 VDR TLR2 SLC11A1 MIR144 IL4 IL18
11 cellular response to interferon-gamma GO:0071346 9.9 TLR2 IL12RB1 IL12B CCL3
12 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.87 TLR2 IL18 IL12B
13 positive regulation of T cell proliferation GO:0042102 9.86 IL4 IL2RA IL2 IL12B
14 positive regulation of tumor necrosis factor production GO:0032760 9.85 TLR2 IL12B CCL3
15 positive regulation of phagocytosis GO:0050766 9.84 SLC11A1 MBL2 IFNG
16 positive regulation of interleukin-6 secretion GO:2000778 9.84 TLR2 MIR144 IFNG
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 IL4 IL2 IL18 IL12B IFNG
18 positive regulation of B cell proliferation GO:0030890 9.82 IL4 IL2 ADA
19 lipopolysaccharide-mediated signaling pathway GO:0031663 9.81 TLR2 IL18 CCL3
20 interleukin-12-mediated signaling pathway GO:0035722 9.81 IL12RB1 IL12B IL10 IFNG
21 positive regulation of defense response to virus by host GO:0002230 9.8 IL4 IL12RB1 IL12B
22 defense response to protozoan GO:0042832 9.79 SLC11A1 IL12B IL10
23 positive regulation of interleukin-12 production GO:0032735 9.79 TLR2 IL12B IFNG
24 positive regulation of interleukin-10 production GO:0032733 9.78 TLR2 IL4 IL12B
25 positive regulation of tumor necrosis factor secretion GO:1904469 9.77 MIR144 IFNGR1 IFNG
26 positive regulation of interferon-gamma production GO:0032729 9.77 SLC11A1 IL2 IL18 IL12RB1 IL12B
27 natural killer cell activation GO:0030101 9.76 IL2 IL18 IL12B
28 microglial cell activation GO:0001774 9.76 TLR2 IL4 IFNGR1 IFNG
29 regulation of regulatory T cell differentiation GO:0045589 9.75 IL2RA IL2 IFNG
30 negative regulation of interleukin-17 production GO:0032700 9.74 IL12B IFNG
31 positive regulation of interleukin-17 production GO:0032740 9.74 IL2 IL18 IL12B
32 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.73 IFNGR1 IFNG
33 positive regulation of chemokine biosynthetic process GO:0045080 9.73 IL4 IFNG
34 macrophage activation GO:0042116 9.73 SLC11A1 IL4
35 cell activation GO:0001775 9.73 TLR2 CCL3
36 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.72 IL4 IL10
37 interleukin-2-mediated signaling pathway GO:0038110 9.72 IL2RA IL2
38 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.72 IL18 IL12B
39 positive regulation of MHC class II biosynthetic process GO:0045348 9.72 IL4 IL10 IFNG
40 response to molecule of bacterial origin GO:0002237 9.71 TLR2 IL10
41 negative regulation of amyloid-beta clearance GO:1900222 9.71 IFNGR1 IFNG
42 positive regulation of isotype switching to IgG isotypes GO:0048304 9.71 IL4 IL2
43 T-helper 1 type immune response GO:0042088 9.71 IL18 IL12B
44 negative regulation of T-helper 17 cell differentiation GO:2000320 9.71 IL4 IL2
45 positive regulation of T-helper 1 type immune response GO:0002827 9.71 SLC11A1 IL12RB1 IL12B
46 positive regulation of T cell differentiation GO:0045582 9.71 IL4 IL2RA IL2 ADA
47 interleukin-23-mediated signaling pathway GO:0038155 9.7 IL12RB1 IL12B
48 positive regulation of smooth muscle cell apoptotic process GO:0034393 9.7 IL12B IFNG
49 positive regulation of natural killer cell proliferation GO:0032819 9.7 IL18 IL12B
50 positive regulation of T-helper 17 type immune response GO:2000318 9.69 IL12RB1 IL12B

Molecular functions related to Pulmonary Tuberculosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.32 VDR TLR2 PGM1 NAT2 MBL2 INHA
2 cytokine receptor activity GO:0004896 9.5 IL12RB1 IL12B IFNGR1
3 growth factor activity GO:0008083 9.35 INHA IL4 IL2 IL12B IL10
4 cytokine binding GO:0019955 9.33 IL12RB1 IL12B IFNGR1
5 interleukin-12 receptor binding GO:0005143 9.26 IL12RB1 IL12B
6 cytokine activity GO:0005125 9.23 INHA IL4 IL2 IL18 IL12B IL10
Sources

Sources for Pulmonary Tuberculosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....